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Abstract—Objective: Inappropriate dosing of patients with
antibiotics is a driver of antimicrobial resistance, toxicity, and
poor outcomes of therapy. In this paper, we investigate, in silico,
the hypothesis that the use of a closed-loop control system could
improve the attainment of pharmacokinetic-pharmacodynamic
targets for antimicrobial therapy, where wide variations in target
attainment have been reported. This includes patients in critical
care, patients with renal disease and patients with obesity.
Methods: The presented in silico study focuses on vancomycin
delivery, a first line therapy for Methicillin-resistant Staphylo-
coccus aureus (MRSA) that has serious side effects, including
nephrotoxicity. For this purpose, an in silico platform for the
simulation of pharmacokinetics of vancomycin agents was devel-
oped including 24 virtual non-critically ill adult subjects obtained
from routinely collected data from two prospective audits of
vancomycin therapy. Intra-day variability on renal clearance,
sensor error and infusion constraints were taken into account.
Proportional Integral Derivative (PID) controller was chosen
because of its simplicity of implementation and satisfactory
performance.
Results: Even though significant intra-day variability and sensor
error were considered in the simulations, by assuming a minimum
inhibitory concentration of 1 mg/l for MRSA, the proposed
controller was able to reach the well-established therapeutic
target of 24-hour area under curve to minimum inhibitory
concentration ratio equal to 400 mg · h/l for all the studied
subjects, while staying significantly below toxic levels.
Conclusion: A PID controller has the potential to precisely deliver
a vancomycin therapy in a non-critically ill adult population.
Significance: Closed-loop control for precision Vancomycin de-
livery can potentially reduce toxicity and poor therapeutic
outcomes, as well as reduce antimicrobial resistance.
Index Terms—Antimicrobial resistance, closed-loop control,
PID control, precision medicine
I. INTRODUCTION
Antimicrobial agents (i.e., drugs that kill or stop the growth
of microorganisms including bacteria, thereby treating infec-
tions) commonly used to treat infections are becoming less
effective over time as bacteria develop resistance to them.
Antimicrobial usage leads to the development and spread
of antimicrobial resistance [1]. This is a major threat to
patient safety with over 700,000 people dying because of drug
resistant infections each year. By 2050, it is estimated that
this figure could be as high as 10 million deaths per year.
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To conserve the effectiveness of antimicrobials we need to
develop ways to use them more effectively [2]. One way to
do this is ensure that we are providing the best dose (i.e.,
amount of drug) of an antimicrobial to kill the organism
causing infection, whilst ensuring that we do not cause toxic
side effects or promote the growth of antimicrobial resistance
through giving too much or too little of a treatment.
A growing body of evidence is emerging to suggest that we
are failing to dose patients appropriately with many commonly
used antimicrobial agents [3], [4]. This has led to calls for
the development of individualised antimicrobial regimens that
consider intra- and inter-individual variation which drives ob-
served drug pharmacokinetic (PK) variation. Despite evidence
that optimisation of antimicrobial PK can improve patient
outcomes in secondary care [3], very little progress has been
made outside of controlled trial environments. The implemen-
tation of individualised dosing has been challenging for several
reasons. This includes, difficulties in access and availability of
appropriate antimicrobial assays, poor integration of dosing
software into electronic health records and decision support
systems, the reliance on transport of blood products for
laboratory analysis, and the technical nature of population
PK with very few healthcare professionals with knowledge
of this field. There is clinical evidence that the administration
of vancomycin for the treatment of Gram-positive infections
by continuous infusion is associated with a significantly lower
risk of nephrotoxicity and better clinical outcomes of infection
when compared with intermittent infusion of the drug [5]
[6]. Therefore, we strongly believe that the development of a
closed-loop antimicrobial delivery system will help to address
these challenges, allowing the wide-scale practice of precision
prescribing and delivery of antimicrobial agents.
The concept of automated drug delivery (i.e., closed-loop
control) is well described and has been successfully applied
in different fields such as controlling blood glucose levels in
diabetes [7] and in delivering anaesthetic drugs for automated
sedation [8]. However, to our knowledge, no work has been
done for automated antimicrobial delivery. Figure 1 shows a
graphical representation of a generic system for automated
closed-loop drug delivery in a hospital setting.
In this work, we evaluate the feasibility of a closed-loop
controller for precision antimicrobial dosing. The system is
composed of: a continuous sensor for measuring antimicro-
bial concentration in blood, or interstitial fluid; a control
algorithm that computes the antimicrobial dose based on
the antimicrobial concentration; and a delivery system (e.g.
intravenous pump) used to administer the antimicrobial drug.
0018-9294 (c) 2017 IEEE. Personal use is permitted, but republication/redistribution requires IEEE permission. See http://www.ieee.org/publications_standards/publications/rights/index.html for more information.
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI 10.1109/TBME.2017.2787423, IEEE
Transactions on Biomedical Engineering
IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING 2
CONTROLLER
SENSOR
PUMP
Fig. 1: Graphical representation of a generic system for
automated closed-loop drug delivery in a hospital setting.
This work clearly falls in this field of personalized medicine,
also termed precision medicine, since it tailors the treatment
to the individual patient rather than to the population [9].
This work assumes the availability of a continuous sensor
for measuring antimicrobial concentration in blood, which
at the moment it is not commercially available. However,
significant research is currently ongoing towards developing a
minimally invasive (e.g. subcutaneous) sensor [10] [11] [12],
[13]. Finally, the selected route for delivering the antimicrobial
agent (i.e., vancomycin) was intravenously.
II. METHODS
A. Closed-loop controller
Closed-loop control systems work on the principle of
feedback in which a signal (e.g. drug concentration) to be
controlled is compared to a reference signal (e.g. therapeutic
drug concentration). The error between the two signals is then
used to tabulate a corrective action (e.g. increase or decrease
drug dosage). Figure 2 shows a block diagram of the pro-
posed closed-loop control system for precision antimicrobial
delivery.
Patient
PK/PD Sensor
Controller+
-­‐
Set-­‐point PumpError Command Drug
Drug	  Concentration
Drug
Fig. 2: Block diagram corresponding to a closed-loop control
system for precision antimicrobial delivery.
In this work, a Proportional Integral Derivative (PID)
closed-loop controller has been chosen. This was considered
adequate given the dynamics of the system to be controlled,
which do not include significant time delays, and due to its
simplicity of implementation. However, other control strate-
gies (e.g. model predictive control) could also have been
employed. A PID controller is described by Equation 1.
u(t) = Kpe(t) +Ki
∫ t
0
e(τ)dτ +Kd
de(t)
dt
, (1)
where u represents the rate of infusion into the central
compartment (e.g. blood); e is the error between the process
variable to control (PV ) (i.e. drug concentration) and the
set point (SP ) (i.e. e(t) = PV (t) − SP (t)); Kp, Ki and
Kd denote the coefficients for the proportional, integral, and
derivative terms, respectively. Finally, the coefficients of the
PID controller are related as Kd = Kp/Td and Ki = KpTi,
where Td and Ti are tunable time constants.
B. Simulation model
To test the selected PID controller for precision antimi-
crobial delivery, an in silico platform for the simulation of
the pharmacokinetics (PK) of the chosen antimicrobial agent
was developed in Matlab (Matworks, Natick, MA, US). Phar-
macokinetics (PK) describes the relationship between drug-
dosing and the drug concentration-time profile in the body.
Drug concentration refers to the amount of drug in a given
volume of blood plasma, described in milligrams per litre
(mg/L). In general, PK models show the movement and fate
of a drug in a biological system after it has been administered.
In this work, the antimicrobial agent vancomycin was selected
since there is a detailed understanding of its clinical utility
given that therapeutic drug monitoring is routinely performed
for this drug in routine practice. Vancomycin is a glycopeptide
antimicrobial chemotherapeutic agent typically used in the
treatment of Staphylococcus aureus infections which show
a resistance to beta-lactams. It is the first line therapy for
Methicillin-resistant Staphylococcus aureus (MRSA), but has
some serious side effects including nephrotoxicity. This is a
particular problem in patients with impaired renal function,
if used drug concentrations are not closely monitored and
controlled. Hence the importance of dosing it appropriately.
A two-compartment model was chosen to model the PK of
vancomycin [14]. A two-compartment model, as the name
implies, has two compartments, a central one, representing
blood and well perfused organs, and a peripheral compartment,
representing poorly perfused tissues like muscle or fat tissue.
The schematic of the two-compartment model is shown in
Figure 3.
Fig. 3: Two-compartment Model
When the drug is introduced into the body, it first reaches
the central compartment and subsequently moves into the
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peripheral compartment shown by the transfer rate constant
kcp. The movement of drug between the two compartments
can be represented either with inter-compartmental clearance,
or in terms of transfer rate constants, kcp and kpc. The volume
of the peripheral compartment is given by
Vp =
kcp
kpc
Vc, (2)
where kcp is the first order transfer rate constant from central
to peripheral compartment; kpc is the first order transfer rate
constant from peripheral to central compartment; Vp is the
volume of peripheral compartment; and Vc is the volume
of central compartment. The rate of change of the drug
concentrations in any compartment is equal to the net sum
of the rates of drug transfer into the compartment minus the
sum of rates of drug transfer out of the compartment. Hence
the differential equations for the simplest case of a intravenous
(IV) bolus administration can be represented as follows.
The rate of change in the central compartment is described
by
dCc(t)
dt
= u(t) + kpcCp(t)− kcpCc(t)− keCc(t), (3)
and in the peripheral compartment by
dCp(t)
dt
= kcpCc(t)− kpcCp(t), (4)
where Cc is the amount of drug in central compartment and
Cp is the amount of drug in peripheral compartment. ke is the
elimination rate constant computed as ke = Cl/Vc, with Cl
the patient’s renal clearance. u is the intravenous drug infusion
rate. Finally, a forward Euler’s method with 1-minute step size
was used to simulate the model.
C. Parameter identification
The parameters of the chosen two-compartment model
were identified using data obtained from non-critically ill
patients managed in three hospitals in North West London
(UK). Routinely collected data from two prospective audits
of vancomycin therapy were interrogated. Identified subjects
not on renal replacement therapy had their demographic and
therapeutic drug monitoring (TDM) data extracted for analysis.
Age, gender, ethnicity, body weight, height, and glomeru-
lar filtration rate (GFR), were all collected for investigation
as model covariates. A total of 24 patients were included.
Median (range) age (years) of the included subjects was
56.5 (21 − 87) with the majority being male (18/30, 60%).
Mean (STD) height (cm) was 168 (11), and the total mean
(STD) body weight (kg) was 74 (15). Median (IQR) GFR was
75.85 (38.8−107.8)ml/min/1.73m2. Since a complete set of
data is only available for each patient at the onset of treatment,
parameters were assumed to stay constant throughout the
treatment period for analysis of the dataset [4]. Population
and individual pharmacokinetic parameters we estimated with
Pmetrics, an R programming language package developed by
the USC Laboratory of Applied Pharmacokinetics (LAPK)
(Los Angeles, CA, US) for non-parametric and parametric
PK-PD modelling and simulation [15]. Figure 4 shows the
observed vs. predicted graphs for two-compartment model
without covariates (R2=0.857). The distribution (i.e., mean
(STD)) of the identified parameters was: Cl = 2.7 (1.5) l/h,
Vc = 27.6 (6.7) L, kcp = 1.2 (1.0) h−1 and kpc = 3.7(2.7)
h−1. Individual posterior estimated PK parameters can be
found in Table I.
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Fig. 4: Observed vs. Predicted plot for the two-compartment
model
D. Pharmacokinetic target
Pharmacokinetic-pharmacodynamic (PK-PD) indices are
used to determine the likelihood of therapeutic success for
the individual patient. Vancomycin displays concentration-
dependent antibacterial activity. The 24-hour Area Un-
der Curve (AUC24h) to Minimum Inhibitory Concentration
(MIC) ratio (AUC24h/MIC) is the pharmacodynamic index
that best links drug exposure with the antibacterial effect [14].
Studies have suggested that the clinical and bacteriological
response to vancomycin therapy was superior in patients with
a AUC24h/MIC value of greater than 400 mg · h/l [1].
However, in the UK, most therapeutic drug monitoring (TDM)
guidelines continue to monitor vancomycin based on peak or
trough concentration levels. Such monitoring has been shown
to under achieve acceptable levels in clinical practice [16].
Generally, a trough level higher than 10 mg/l is expected.
This has been shown to correspond to an AUC24h/MIC of
approximately 250 mg · h/l [17]. Therefore, if an organisms
MIC is greater than 0.5 mg/l, the treatment is unlikely to be
therapeutic.
Furthermore, trough levels of greater than 20 mg/L have
been associated with increased risk of nephrotoxicity in pa-
tients receiving therapy. This equates to an AUC24h/MIC of
approximately 700 mg · h/l [17]. Since the most commonly
identified MIC value for Staphylococcus aureus is 1 mg/l, the
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TABLE I: Individual posterior Bayesian estimated pharmacokinetic from the two-compartment model for the 24 virtual subjects.
Subj/Param 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Cl (l/h) 3.6 2.8 3.7 0.2 1.3 1.5 2.7 2.0 2.0 4.8 1.1 1.0 1.3 3.7 1.5 3.3 3.1 7.1 3.8 3.7 3.7 3.8 1.8 1.4
Vc (l) 26.2 24.5 27.6 27.1 38.4 41.6 26.0 20.1 22.8 21.7 32.1 20.0 21.0 29.2 41.5 26.5 20.5 39.8 24.9 26.9 29.0 23.6 31.4 20.7
kcp (h−1) 1.9 1.2 2.2 2.6 0.6 0.07 3.3 0.02 0.02 0.14 1.7 0.04 0.3 2.2 0.08 2.0 1.0 0.1 2.2 2.2 2.2 2.2 0.08 0.4
kpc (h−1) 3.5 5.8 2.9 0.2 4.1 0.1 0.5 9.5 8.4 2.1 5.2 9.3 3.8 2.2 0.1 3.0 5.9 0.05 3.9 3.2 2.3 4.4 4.5 3.8
AUC24h/MIC most often will simply becomes dependent on
AUC24h.
E. Intra-patient variability
During the course of antimicrobial treatment, the patient’s
condition can significantly change (e.g. dehydration). For ex-
ample, patients renal clearance (Cl) can vary during treatment
due to impaired renal function. Variation in Cl will have an
impact on the amount of drug in the system due to the lack
of ability to clear it. If doses are not adjusted accordingly,
this may cause an accumulation of drug resulting in increased
risk of developing toxicity. Vancomycin is almost completely
renally cleared and thus total body clearance of the drug is
dependent on the kidney, and is correlated with glomerular
filtration rate and creatinine clearance [18], [19]. Therefore, the
controller should be able to account for variations in Cl and
rectify the doses accordingly to achieve the necessary target
AUC. For this purpose, intra-day variability affecting renal
clearance have been introduced by means of the time varying
function
Cl(t) = ACl0 sin
(
2pi
1440
t+ 2piφ
)
, (5)
where Cl0 is the identified clearance parameter, A is the
amplitude of the variation and φ is a randomly generated
number per individual between 0 and 1. In particular, A was
set to 0.2 to model a 20% variability in clearance. Figure 5
shows a a particular example of renal clearance variability over
24 h.
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Fig. 5: Variation of renal clearance (Cl) over time for a
particular virtual patient.
F. Variable set-point
Since the objective is to achieve the PK target
AUC24h/MIC of 400 mg · h/l, the closed-loop controller
target (SP ), i.e. plasma drug concentration, should be set to
400/24 mg/l along the 24 hours. It is important to remark that
the closed-loop controller is delivering a continuous infusion
in this scenario. However, this target is not realistic due to the
transient response, intra-subject variability, and perturbation in
the system. Therefore, the set-point needs to be recalculated
overtime in order to achieve the desired AUC24h/MIC target.
For this purpose, a six-hour window was chosen to recalculate
the set-point to let enough time to pass the transient response.
The set-point at time t (hours) is recalculated as expressed by
Equation 6.
SP (t) =
1
MIC
AUC24h −
∫ t
0
Cc(τ)dτ
24− t . (6)
Finally, we aimed for 95% of patients to achieve the target
of a 95 % of the patients were aimed to achieve the target
380 < AUC24h/MIC < 420 mg · h/l during simulated
therapy. Note that a AUC24h/MIC slightly above or below
400 mg · h/l is equally effective from a therapeutic point of
view.
G. Sensor error and pump constraints
As previously mentioned, a continuous sensor for measuring
antimicrobial concentration in blood, or interstitial fluid, is not
commercially available. Therefore, it is currently not possible
to precisely know the sensor dynamics and accuracy of such
a sensor. In this work, we consider the existence of a subcuta-
neous continuous sensor the dynamics of which are assumed to
be similar to that of a glucose sensor reported by Breton et al
[20]. In particular, the characteristics of the employed sensor
error were: mean±SD of -2.1±5.7%; interquartile range of
6.9%; and minimum and maximum of -21.7% and 38.4%,
respectively. Figure 6 show an example of the sensor error
dynamics over a 24-hour scenario. Finally, a ±2% infusion
error and a maximum infusion rate of 999 ml/h were chosen
for the virtual infusion pump, which corresponds to an Alaris
Syringe (Becton Dickinson, St Albans, UK).
H. Tuning and initialisation
Regarding the two-compartment simulation model, the ini-
tial concentrations in the central and peripheral compartments
were assumed to be 0 mg/l. The parameters of the PID
controller were manually tuned and fixed to Kp = 0.1,
Ti = 0.5, Td = 1 and Ti = 0 for all subjects. The integral
error of the PID controller was calculated over a sliding time
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Fig. 6: Sensor error dynamics over a 24-hour scenario.
window of six hours. The duration of the simulation was
24 hours and the sensor sampling time was assumed to be
every 15 minutes. Renal clearance variability and sensor noise
were randomly generated for each patient. Finally, the initial
vancomycin infusion rate was assumed to be 1 mg/min.
III. RESULTS
Figure 7 shows the plasma vancomycin concentration pro-
files for the 24 studied virtual patients over 24 hours. Figure
8 shows the corresponding drug infusion rate. The observed
oscillations on drug concentration levels and on infusion rate
are partly due to the variations in renal clearance, sensor
error and variable set-point. Maximum vancomycin dose de-
livered over 24 hours was 4260 mg, which is higher than the
maximum recommended dose (i.e., 3000 mg). However, the
attained AUC24h/MIC levels were significantly below the
toxic threshold (i.e. 700 mg ·h/l) [17]. Finally, Figure 9 shows
the corresponding cumulative AUC/MIC over 24 hours. At
the end of the simulation, the defined target was achieved
for all 24 virtual subjects. It is worth remarking that when
the variable set-point was not taken into account, none of the
patients achieved the target.
IV. DISCUSSION
The presented study provides an in silico proof-of-concept
for the use of a closed-loop system to optimise vancomycin
delivery in a non-critically ill patient cohort. However, there
are some limitations in this analysis that need to be mentioned.
First of all, the data set used to identify the PK model to carry
out the in silico study is relatively small (n=24). Therefore,
the obtained virtual cohort might not be represent the whole
spectrum of non-critically ill patients.
Although intra-day variability in renal clearance and sensor
error have been taken into account in the simulations, other
sources of variability and uncertainty would probably be
present in a real scenario, which might further challenge the
performance of the controller, such as sensor artefacts or pump
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Fig. 7: Vancomycin plasma concentration over 24 hours cor-
responding to the 24 studied virtual patients.
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Fig. 8: Vancomycin delivery rate over 24 hours corresponding
to Figure 7
occlusions. Furthermore, further tests should be carried out
with a model of an actual subcutaneous vancomycin sensor.
Adjusting the varying set-point has been proven to be an
effective strategy to attain the AUC24h/MIC target. However,
this strategy might induce abrupt changes in the set-point
which can cause an overaggressive control action. Although
this has not been an issue within this study, it could be easily
resolved in future scenarios by saturating the derivative term of
the PID controller. A unique tuning of the PID has been proven
to be sufficient for attaining the desired target. However,
individualised tuning could lead to even better performance
of the controller (e.g. less overshoot). In addition, this tuning
could be based on patient demographics and therapeutic drug
monitoring data.
It is well stablished that in silico studies are not a re-
placement to clinical trials. However, they can be very useful
tool to speed up, and reduce cost, in the development of
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Fig. 9: Cumulative AUC/MIC over 24 hours corresponding
to Figure 7.
automated drug delivery systems [21]. Finally, the proposed
approach could be easily extrapolated to the delivery of other
antimicrobial drugs.
V. CONCLUSIONS AND FUTURE WORK
A closed-loop system for precision vancomycin delivery
composed by a PID controller, a subcutaneous sensor and
an intravenous pump has the potential to improve infection
outcomes in a non-critically ill population. In particular, an
in silico study including 24 virtual subjects, showed that the
proposed controller was able to reach the well-established
therapeutic target of AUC24h/MIC equal to 400 mg ·h/l for
all the studied subjects. Future work includes the comparison
of the proposed PID controller against other closed-loop
controllers such as Model Predictive Control (MPC). Finally,
the proposed closed-loop system is planned to be clinically
validated using a micro-array-based real-time sensor for the
continuous measurement of antimicrobial concentration in the
dermal interstitial fluid, which is currently being developed by
our group.
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